333 related articles for article (PubMed ID: 16936720)
1. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.
Putt KS; Chen GW; Pearson JM; Sandhorst JS; Hoagland MS; Kwon JT; Hwang SK; Jin H; Churchwell MI; Cho MH; Doerge DR; Helferich WG; Hergenrother PJ
Nat Chem Biol; 2006 Oct; 2(10):543-50. PubMed ID: 16936720
[TBL] [Abstract][Full Text] [Related]
2. Flipping the safety catch of procaspase-3.
Porter AG
Nat Chem Biol; 2006 Oct; 2(10):509-10. PubMed ID: 16983381
[No Abstract] [Full Text] [Related]
3. Procaspase-activating compound 1 induces a caspase-3-dependent cell death in cerebellar granule neurons.
Aziz G; Akselsen ØW; Hansen TV; Paulsen RE
Toxicol Appl Pharmacol; 2010 Sep; 247(3):238-42. PubMed ID: 20638399
[TBL] [Abstract][Full Text] [Related]
4. Cell death induced by novel procaspase-3 activators can be reduced by growth factors.
Boldingh Debernard KA; Aziz G; Gjesvik AT; Paulsen RE
Biochem Biophys Res Commun; 2011 Sep; 413(2):364-9. PubMed ID: 21893038
[TBL] [Abstract][Full Text] [Related]
5. Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.
Wang F; Liu Y; Wang L; Yang J; Zhao Y; Wang N; Cao Q; Gong P; Wu C
J Cell Mol Med; 2015 Aug; 19(8):1916-28. PubMed ID: 25754465
[TBL] [Abstract][Full Text] [Related]
6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
7. SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.
Chen Y; Sun M; Ding J; Zhu Q
Cancer Chemother Pharmacol; 2016 Sep; 78(3):643-54. PubMed ID: 27488460
[TBL] [Abstract][Full Text] [Related]
8. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.
Peterson QP; Hsu DC; Goode DR; Novotny CJ; Totten RK; Hergenrother PJ
J Med Chem; 2009 Sep; 52(18):5721-31. PubMed ID: 19708658
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antitumor activity of the novel derivatized polyvinyl alcohol-based polymer P10(4).
Raffaghello L; Zuccari G; Carosio R; Orienti I; Montaldo PG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3485-93. PubMed ID: 16740774
[TBL] [Abstract][Full Text] [Related]
10. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
11. Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo.
Martín-Duque P; Quintanilla M; McNeish I; Lopes R; Romero J; Romero D; Lemoine NR; Ramón y Cajal S; Vassaux G
Int J Mol Med; 2006 May; 17(5):841-7. PubMed ID: 16596269
[TBL] [Abstract][Full Text] [Related]
12. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.
Zaman S; Wang R; Gandhi V
Exp Hematol; 2015 Nov; 43(11):951-962.e3. PubMed ID: 26257207
[TBL] [Abstract][Full Text] [Related]
13. Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner.
Huang J; Yang M; Liu H; Jin J
Acta Pharmacol Sin; 2008 Aug; 29(8):951-64. PubMed ID: 18664328
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.
Lucas PW; Schmit JM; Peterson QP; West DC; Hsu DC; Novotny CJ; Dirikolu L; Churchwell MI; Doerge DR; Garrett LD; Hergenrother PJ; Fan TM
Invest New Drugs; 2011 Oct; 29(5):901-11. PubMed ID: 20499133
[TBL] [Abstract][Full Text] [Related]
15. Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.
Botham RC; Fan TM; Im I; Borst LB; Dirikolu L; Hergenrother PJ
J Am Chem Soc; 2014 Jan; 136(4):1312-9. PubMed ID: 24383395
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 3,5,4'-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice.
Pan MH; Gao JH; Lai CS; Wang YJ; Chen WM; Lo CY; Wang M; Dushenkov S; Ho CT
Mol Carcinog; 2008 Mar; 47(3):184-96. PubMed ID: 18085528
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036.
Shiah HS; Lee WS; Juang SH; Hong PC; Lung CC; Chang CJ; Chou KM; Chang JY
Biochem Pharmacol; 2007 Mar; 73(5):610-9. PubMed ID: 17150195
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
19. Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma.
Sarkar A; Balakrishnan K; Chen J; Patel V; Neelapu SS; McMurray JS; Gandhi V
Oncotarget; 2016 Jan; 7(3):3461-76. PubMed ID: 26658105
[TBL] [Abstract][Full Text] [Related]
20. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
